Rofo 2021; 193(08): 928-936
DOI: 10.1055/a-1348-1932
Interventional Radiology

Chemosaturation with Percutaneous Hepatic Perfusion: Outcome and Safety in Patients with Metastasized Uveal Melanoma

Article in several languages: English | deutsch
Cornelia Lieselotte Angelika Dewald
1  Institute for Diagnostic and Interventional Radiology, Hannover Medical School, MHH, Hannover, Germany
,
1  Institute for Diagnostic and Interventional Radiology, Hannover Medical School, MHH, Hannover, Germany
,
Lena Sophie Becker
1  Institute for Diagnostic and Interventional Radiology, Hannover Medical School, MHH, Hannover, Germany
,
Sabine Maschke
1  Institute for Diagnostic and Interventional Radiology, Hannover Medical School, MHH, Hannover, Germany
,
Timo C. Meine
1  Institute for Diagnostic and Interventional Radiology, Hannover Medical School, MHH, Hannover, Germany
,
Anna Saborowski
2  Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, MHH, Hannover, Germany
,
Leon Jonas Schönfeld
2  Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, MHH, Hannover, Germany
,
Arndt Vogel
2  Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, MHH, Hannover, Germany
,
Martha M. Kirstein
3  1st Department of Medicine, University Medical Center Schleswig-Holstein Lübeck Campus, Lübeck, Germany
,
Frank K. Wacker
1  Institute for Diagnostic and Interventional Radiology, Hannover Medical School, MHH, Hannover, Germany
› Author Affiliations

Abstract

Purpose Chemosaturation percutaneous hepatic perfusion (CS-PHP) allows selective intrahepatic delivery of high dose cytotoxic melphalan in patients with curatively untreatable liver tumors while limiting systemic toxicity through hemofiltration of the hepatic venous blood. Aim of this study was to investigate the response to therapy, survival and safety of the CS-PHP procedure in patients with liver-dominant metastatic uveal melanoma (UM).

Materials and Methods Overall response rate (ORR) and disease control rate (DCR) were assessed according to Response Evaluation Criteria In Solid Tumors (RECIST1.1). Median overall survival (mOS), median progression-free survival (mPFS) and hepatic progression-free survival (mhPFS) were analyzed using Kaplan-Meier estimation. Adverse events were evaluated with Common Terminology Criteria for Adverse Events (CTCAE) v5.

Results Overall, 30 patients were treated with 70 CS-PHP in a salvage setting from October 2014 to January 2019. In total, ORR and DCR were 42.3 % and 80.8 %, respectively. Overall, mOS was 12 (95 % confidence interval (CI) 7–15) months, and both, mPFS and mhPFS were 6 months, respectively (95 % CI 4–10; 95 % CI 4–13). Adverse events (AE) most frequently included significant but transient hematologic toxicities (87 % of grade 3/4 thrombocytopenia), less frequent AEs were hepatic injury extending to liver failure (3 %), cardiovascular events including one case of ischemic stroke (3 %).

Conclusion Salvage treatment with CS-PHP is effective in selected patients with UM. The interventional procedure is safe. Serious hepatic and cardiovascular events, although rare, require careful patient selection and should be closely monitored.

Key Points:

  • CS-PHP is safe for selected patients with liver-dominant metastatic uveal melanoma.

  • CS-PHP resulted in hepatic disease control in 80 % of patients.

  • Hematologic events following CS-PHP are common but manageable.

Citation Format

  • Dewald CL, Hinrichs JB, Becker LS et al. Chemosaturation with Percutaneous Hepatic Perfusion: Outcome and Safety in Patients with Metastasized Uveal Melanoma. Fortschr Röntgenstr 2021; 193: 928 – 936



Publication History

Received: 21 July 2020

Accepted: 04 January 2021

Publication Date:
03 February 2021 (online)

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany